 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
174 News |  |
| «123 |
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Day 2 at @BSCCardiology #EP101 course, was great, lots of information feel like I need a long nap to absorb all of it. Thanks to Dr. Estes, @narrowQRS @cooper_dh @JRWinterfield @DrBradleyKnight @Ed_Gerst and Dr. Tomaselli for making some keys concepts easier to understand. (Twitter) - May 31, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Fascinating talk on biophysics of ablation with @Ed_Gerst at #EP101. Underscored how physics and technology are intertwined with physiology in our field. Have to understand all of it! (Twitter) - May 31, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Thank you to all the attendings and 3T Fellows for their presentations and discussion! #EP101 #ACCFIT #Epeeps (Twitter) - May 31, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Overall a great day, with stellar presentations by @cooper_dh @JRWinterfield @DrBradleyKnight @Ed_Gerst and some "less hip" faculty who lack Twitter handles! 😜 #EP101 (Twitter) - May 31, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
As always, great teaching presentations from @DrBradleyKnight !! Gotta love the Superman pose! 😁 #EP101 (Twitter) - May 31, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Ablation of typical flutter with @DrBradleyKnight #EP101. Note this slide was kept up < 10s to prevent the crowd from becoming too excited. (Twitter) - May 31, 2019
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Differentiating tachycardias with @DrBradleyKnight at the #EP101 course. Focus on the numbers close to 0 and 100 that’s where the 💰 is. (Twitter) - May 31, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Many thanks for invite @BSCCardiology @narrowQRS and Dr Estes for #EP101 in Boston. Tough but critical concept that all #EPeeps contemplate throughout career. @Ed_Gerst @Zo_EP2 @DrFerminGarcia @DrGregMichaud @DrBradleyKnight (Twitter) - May 31, 2019
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
Clinical: How sad. We teach our lay-person pts about EP every day. Someone who says they can't teach a cardiology fellow either is a horrendously bad teacher, or doesn't understand the concepts well enough themselves. The upcoming #EP101 course is the premier EP venue for gen card fellows! (Twitter) - May 18, 2019
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Dainippon, Pari
@RKalhan Hi Dr. Kalhan, happy Friday! I'm reaching out on behalf of Sunovion regarding a unique opportunity to learn about LONHALA MAGNAIR. Hoping to discuss in more detail via phone or email at your earliest convenience! (Twitter) - Apr 12, 2019
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
New P2 trial: Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Nov 1, 2016
P2, N=12, Completed, Sponsor: Sunovion Respiratory Development Inc.
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, glycopyrrolate inhalation (CHF 5259) / Chiesi
New P2 trial: Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Oct 27, 2016
P2, N=42, Completed, Sponsor: Sunovion Respiratory Development Inc.
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Trial completion: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri (clinicaltrials.gov) - May 9, 2016
P1, N=30, Completed, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Completed
- ||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: GOLDEN-5: A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Mar 21, 2016
P3, N=1087, Completed, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
Enrollment open, Trial primary completion date: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri (clinicaltrials.gov) - Feb 3, 2016
P1, N=30, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016
- ||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (clinicaltrials.gov) - Dec 23, 2015
P3, N=641, Completed, Sponsor: Sunovion Respiratory Development Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2016 --> Apr 2016 Active, not recruiting --> Completed
- ||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: GOLDEN-3: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Nov 19, 2015
P3, N=653, Completed, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment closed: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (clinicaltrials.gov) - Sep 25, 2015
P3, N=645, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment closed: GOLDEN-3: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Aug 26, 2015
P3, N=645, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment closed: GOLDEN-5: A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Aug 26, 2015
P3, N=1050, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari, Seebri Breezhaler (glycopyrronium bromide) / Novartis, Vectura, Sosei
New P1 trial: GOLDEN7: Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri (clinicaltrials.gov) - Jul 30, 2015
P1, N=30, Not yet recruiting, Sponsor: Sunovion Respiratory Development Inc.
- |||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment open: GOLDEN-3: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Feb 26, 2015
P3, N=645, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment open: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (clinicaltrials.gov) - Feb 26, 2015
P3, N=645, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P3 trial: GOLDEN-3: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Jan 28, 2015
P3, N=645, Not yet recruiting, Sponsor: Sunovion Respiratory Development Inc.
- |||||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P3 trial: Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4) (clinicaltrials.gov) - Jan 28, 2015
P3, N=645, Not yet recruiting, Sponsor: Sunovion Respiratory Development Inc.
- |||||||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P3 trial: GOLDEN-5: A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD (clinicaltrials.gov) - Oct 28, 2014
P3, N=1050, Recruiting, Sponsor: Sunovion Respiratory Development Inc.
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial primary completion date: GOLDEN 6: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (clinicaltrials.gov) - May 14, 2014
P2, N=96, Completed, Sponsor: Sunovion Respiratory Development Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> May 2014
- || Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion date: GOLDEN 6: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (clinicaltrials.gov) - May 14, 2014
P2, N=96, Completed, Sponsor: Sunovion Respiratory Development Inc.
Trial primary completion date: Jun 2014 --> May 2014 Trial completion date: Jun 2014 --> May 2014
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: GOLDEN 6: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (clinicaltrials.gov) - May 14, 2014
P2, N=96, Completed, Sponsor: Sunovion Respiratory Development Inc.
Trial completion date: Jun 2014 --> May 2014 Active, not recruiting --> Completed
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment change: Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study (clinicaltrials.gov) - Apr 9, 2014
P2, N=275, Completed, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Completed N=140 --> 275
- ||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Enrollment closed: GOLDEN 6: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (clinicaltrials.gov) - Feb 3, 2014
P2, N=96, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
N=140 --> 275 Recruiting --> Active, not recruiting
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P2 trial: GOLDEN 6: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (clinicaltrials.gov) - Jan 15, 2014
P2, N=96, Active, not recruiting, Sponsor: Sunovion Respiratory Development Inc.
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: GOLDEN-2: A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Apr 17, 2013
P2, N=275, Completed, Sponsor: Sunovion Respiratory Development Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P2 trial: GOLDEN-2: A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov) - Oct 11, 2012
P2, N=275, Completed, Sponsor: Sunovion Respiratory Development Inc.
- |||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
Trial completion: Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study (clinicaltrials.gov) - Dec 30, 2011
P2, N=140, Completed, Sponsor: Sunovion Respiratory Development Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lonhala Magnair (glycopyrrolate) / Sumitomo Pharma, Pari
New P2 trial: Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study (clinicaltrials.gov) - Aug 28, 2011
P2, N=140, Completed, Sponsor: Sunovion Respiratory Development Inc.